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Abstract: Background: There is currently no standard 
treatment for desmoid tumors (DTs) associated with famil-
ial polyposis coli (FAP). Familial adenomatous polyposis 
in DT patients is sometimes a life-threatening condition.
Methods: We enrolled all consecutive patients with FAP 
treated at Unit of General Surgery and Transplant, Univer-
sity of Naples Federico II and evaluated the incidence of 
DTs on FAP between 1996 and 2016.
Results: We observed 45 consecutive patients with FAP; 
of these 5 were DT-FAP-associated. All 5 cases with FAP 
were young women, age 25 to 65 years, previously treated 
by colectomy. Of these, 4 patients presented a parietal 
localization and had been treated with a wide surgical 
exeresis; one patient had an intra-abdominal, mesenteric 
tumor that was unresectable at laparotomy. We performed 
CT-guided drainage, ureteral stenting, medical therapy 
(sulindac+tamoxifene), and chemotherapy (dacarba-
zine+doxorubicine).
All patients were alive and underwent follow-ups for 5 
years post-surgery; only 1 patient with parietal localiza-
tion showed a local relapse after 2 years.
Conclusions: We propose a modulated approach to the 
single patient with FAP, with surgery as treatment of 
choice for parietal localization disease and integrating 
different kinds of therapies (surgery alone or associated 
with RT, CT) for the intra-abdominal tumor.
Keywords: Desmoid tumor; Familial adenomatous poly-
posis; Radiotherapy; Surgery
1  Background
In 1838 Johannes Mueller first described a desmoid 
tumor (DT) as a neoplasia arising from tendons, ban-
dlike in shape, with local aggressiveness and possi-
bility of recurrence [1]. Patients with familial adenoma-
tous polyposis (FAP) may develop soft-tissue tumors, 
DTs. These tumors are considered benign but can be 
life threatening through progressive enlargement and 
consequently, pressure on gastrointestinal or urinary 
tracts, nervous or vascular systems.
DTs can arise in the mesentery, abdominal wall, or 
areas of scars; they are considered a benign entity but 
can cause severe morbidity and mortality because of their 
progressive growth that threatens the intra-abdominal 
organs, nerves, and vessels [2]. They occur in about 10% 
to 25% of FAP patients, commonly in women, and are one 
of the most important causes of death after colectomy [3].
FAP is an inherited syndrome that, with other similar 
neoplasms such as Lynch syndrome, MUTYH-associated 
polyposis (MAP), and several hamartomatous polyposis con-
ditions, accounts for about 3% to 6% of all colorectal cancers 
[3-7]. The etiopathogenesis is still unknown, but there are 
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different hypotheses, including genetic alterations [8,9] 
and/or an endocrinological  or traumatic genesis [10-12].
However, several doubts about therapy and manage-
ment of FAP have been reported [13].The surgical approach 
is the first therapeutic step, but the unfavorable biologic 
characteristics of desmoids do not always allow a wide 
excision; therefore, radiotherapy and chemotherapy have 
been tested as the primary definitive treatment or as an 
adjuvant therapy after surgery. Recently, several authors 
reported a cell-based therapeutic approach. A therapy 
with progenitors like endothelial progenitor cells (EPCs), 
using intracellular signals, may impair the adverse tumor 
vascularization [14-20]. In particular, the role of vascular 
endothelial growth factor (VEGF) and its calcium-medi-
ated signaling as a possible target site of anti-angiogenetic 
therapy in EPCs has been addressed [21-30].
2  Methods
We enrolled all the consecutive patients with FAP who 
underwent surgery at the Unit of General Surgery and 
Transplant, University of Naples Federico II and evalu-
ated the incidence of DTs on FAP between years 1996 and 
2016. All procedures applied were in accordance with 
international guidelines, with the standards of the local 
ethics committees, and with the Helsinki Declaration of 
1975, 1983 revision. At the first appointment, each patient 
signed informed consent for the surgical procedure and 
collection and use in clinical research of the data obtained, 
as established by the Ethics Committee of AOU-University 
of Naples Federico II.
All patients at admission submitted to blood exams, 
ultrasound, CT Scan, and fine-needle cytology (FNC) in 
accordance with good clinical practice. The safety and the 
efficacy of surgical treatment were assessed. All patients 
were re-evaluated by periodic follow-ups, including exam-
ination by a physician, chest X-ray, and computed tomog-
raphy abdominopelvic or magnetic resonance imaging 
every 3 months for the first year, every 6 months for the 
following 4 years, and subsequently every year.
3  Results
During the ten years 1996 to 2016 we observed 45 consecu-
tive patients with FAP; of these 5 presented with both FAP 
and DT. These 5 patients were all female, aged between 25 
and 65 years old, and underwent surgery in the previous 3 
to 6 years for FAP: 1 underwent total colectomy combined 
with ileo-rectal anastomosis (IRA) and 4 received a proc-
tocolectomy with ileal pouch-anal  anastomosis (IPAA). 
The demographic and clinical characteristics of the 5 
patients with FAP and DT are shown in Table 1. The des-
moids were located in 2 patients who were members of the 
same family, at rectus abdominis; in 2 cases at the external 
oblique muscle ,and at the mesentery in 1 patient. (Table 1) 
The patients with parietal tumor showed no symp-
toms; they referred only to the onset of a movable and 
painless abdominal mass. One of the desmoids found 
in the external oblique muscle showed bleeding, but 
without anemia. The patient with the mesenteric desmoid 
reported abdominal pain, weight loss, and sub-occlusive 
crises, associated with left hydronephrosis. 
Surgical treatment was possible in all parietal loca-
tions, in the form of wide exeresis. (Table 1, Figure 1). The 
patients were discharged 6 to 8 days after surgery without 
complications. The mesenteric desmoid was unresectable 
at laparotomy because of its connections with the great 
Figure 1. A: Desmoid tumor that arose after total colectomy in the 
anterior abdominal wall in a young FAP-affected female patient:  CT 
scan.
B: Surgical specimen of desmoid tumor that arose after total colec-
tomy in the anterior abdominal wall in a young FAP-affected female 
patient.
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abdominal vessels and small bowel loops. Therefore, the 
patient underwent TC-guided drainage and ureteral stent-
ing to treat the left hydronephrosis and was treated with 
tamoxifen and sulindac. 
One patient received post-operative radiotherapy, 
whereas the others followed an adjuvant therapy with 
sulindac and tamoxifen in the year after the operation. 
After l year of follow-up, the patient was alive and in 
good health, but the tumor had not regressed. Therefore, 
chemotherapy with doxorubicin plus dacarbazine was 
performed; she showed a partial response. At 3 years after 
the initial diagnosis, she is alive with a tumoral regression 
shown on CT scan and DMSA scintigraphy. (Table 2)
The incidence of desmoid tumors developed in 
patients with FAP in our series is 11.1%.
All patients were alive and underwent follow-up for 
5 years; only 1 patient with an external oblique muscle 
localization showed a local relapse after 2 years. 
4  Conclusion
The DT represents an unfortunate event for patient with 
FAP and is the third most frequent cause of death in this 
patient setting. The management of DT is not yet standard-
ized, and it can be different in case of parietal or intra-ab-
dominal locations. Our experience shows how the treat-
ment of these tumors might be particularly challenging. 
In patients with FAP, the risk of desmoid fibromatosis is 
increased up to 800-fold compared with the general pop-
ulation; cumulative risk of onset fibromatosis is 16% in 
the 10 years after colectomy (peak incidence in 1 to 3 years 
following colorectal surgery) [31]. A surgical approach can 
be justified for the parietal locations followed by drugs or 
radiotherapy with a low recurrence rate [32].
In patients with intrabdominal tumors, a modulated 
therapeutic approach (surgery alone or associated with 
RT, CT), or also an abstensionist behavior can be justi-
fied for the unpredictable natural history of this disease, 
characterized sometimes by spontaneous regressions and 
absence of growth of tumor for a long period; even though 
it has been reported that these lesions have an higher rate 
of recurrence when associated with FAP [33].
The role of radiotherapy (RT) is yet not clear. Several 
studies reported the RT efficacy (partial or complete 
tumoral regression), using 50–60 Gy, with a local control 
in 89% and recurrences in 20% to 30% [34-35]. Successes 
could depend on menopausal induction and the conse-
quential estrogenic decrease in women. This hypothesis 
is also supported by the low radiosensitivity observed in 
men.
In our study, we observed only 5 patients with FAP 
and DT among the 45 FAP patients enrolled. In all parietal 
tumors, a wide exeresis was possible with safe margins 
and a minimal rate of recurrence. The surgical treatment 
of desmoids offers some considerations about the possibil-
ity of aggressive procedures and the extension of exeresis, 
when feasible (Figure 1). The biological characteristics of 
desmoids do not always allow a perfect exeresis because 
the nearest structures can be strongly infiltrated at the 
Table 1: Demographic and clinical presentation of the 5 patients with 
FAP and desmoid tumor
PATIENTS’ CHARACTERISTICS N°
AGE (years) 25-65
GENDER
Female
Male
5
0
PREVIOUS SURGERY
Total colectomy with ileo-rectal anastomosis ( IRA )
Proctocolectomy with  ileo-anal anastomosis ( IPAA)
1
4
CLINICAL PRESENTATION
Rectus Abdominis
Palpable mass
Subocclusion and abdominal pain
Bleeding
Hydronephrosis 
2
2
0
0
0
External Oblique Muscle
Palpable mass
Subocclusion and abdominal pain
Bleeding
Hydronephrosis
2
2
0
1
0
Mesentery 
Palpable mass
Subocclusion and abdominal pain
Bleeding
Hydronephrosis
1
0
1
0
1
Table 2: Therapeutic choices
PARIETAL LOCALIZATION, N:
Surgery (wide excision)
Radiotherapy after surgery
Adjuvant Chemotherapy 
(suldinac and tamoxifene)
4
1
1
MESENTERIC LOCALIZATION, N:
Chemotherapy (suldinac and tamoxifene)
Chemotherapy (with doxorubicine and dacarbazine)
1
1
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time of surgery. Thus, it can be necessary to perform a pal-
liative procedure (gastrointestinal bypasses, transuretero-
ureterostomy) [36-39].
In conclusion, our experience supports a modulated 
approach to the single patient, with surgery as treatment 
of choice for parietal localization and integrating differ-
ent kinds of therapies for the intra-abdominal ones. We 
indicate early identification of high-risk subjects, such 
as young women, who are candidates for a restrictive fol-
low-up and an early colectomy. We urge cooperation with 
National FAP Registers [40].
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